Medical - Diagnostics & Research
Compare Stocks
5 / 10Stock Comparison
PRE vs NTRA vs EXAS vs MYRG vs LH
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
Medical - Diagnostics & Research
Engineering & Construction
Medical - Diagnostics & Research
PRE vs NTRA vs EXAS vs MYRG vs LH — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Diagnostics & Research | Medical - Diagnostics & Research | Medical - Diagnostics & Research | Engineering & Construction | Medical - Diagnostics & Research |
| Market Cap | $242M | $31.16B | $20.02B | $6.65B | $21.24B |
| Revenue (TTM) | $69M | $2.31B | $3.25B | $3.82B | $14.14B |
| Net Income (TTM) | $-47M | $-208M | $-208M | $142M | $942M |
| Gross Margin | 47.2% | 64.8% | 69.7% | 11.9% | 27.8% |
| Operating Margin | -62.9% | -13.4% | -6.4% | 5.1% | 11.0% |
| Forward P/E | — | — | 582.8x | 44.0x | 14.5x |
| Total Debt | $2M | $214M | $2.52B | $104M | $7.20B |
| Cash & Equiv. | $32M | $1.08B | $956M | $150M | $532M |
PRE vs NTRA vs EXAS vs MYRG vs LH — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| Prenetics Global Li… (PRE) | 100 | 14.1 | -85.9% |
| Natera, Inc. (NTRA) | 100 | 191.9 | +91.9% |
| Exact Sciences Corp… (EXAS) | 100 | 95.9 | -4.1% |
| MYR Group Inc. (MYRG) | 100 | 446.9 | +346.9% |
| Labcorp Holdings In… (LH) | 100 | 101.4 | +1.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PRE vs NTRA vs EXAS vs MYRG vs LH
Each card shows where this stock fits in a portfolio — not just who wins on paper.
PRE is the #2 pick in this set and the best alternative if growth exposure and sleep-well-at-night is your priority.
- Rev growth 201.7%, EPS growth -14.0%, 3Y rev CAGR 91.5%
- Lower volatility, beta 0.27, Low D/E 1.3%, current ratio 3.01x
- 201.7% revenue growth vs LH's 7.2%
- +205.2% vs LH's +6.1%
NTRA is the clearest fit if your priority is long-term compounding.
- 20.9% 10Y total return vs MYRG's 16.8%
EXAS ranks third and is worth considering specifically for defensive.
- Beta 0.12, current ratio 2.43x
- Beta 0.12 vs MYRG's 1.70
MYRG is the clearest fit if your priority is income & stability.
- Dividend streak 4 yrs, beta 1.70
- 8.7% ROA vs PRE's -23.7%, ROIC 18.3% vs -20.8%
LH carries the broadest edge in this set and is the clearest fit for value and quality.
- Lower P/E (14.5x vs 44.0x)
- 6.7% margin vs PRE's -67.4%
- 1.1% yield; the other 4 pay no meaningful dividend
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 201.7% revenue growth vs LH's 7.2% | |
| Value | Lower P/E (14.5x vs 44.0x) | |
| Quality / Margins | 6.7% margin vs PRE's -67.4% | |
| Stability / Safety | Beta 0.12 vs MYRG's 1.70 | |
| Dividends | 1.1% yield; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +205.2% vs LH's +6.1% | |
| Efficiency (ROA) | 8.7% ROA vs PRE's -23.7%, ROIC 18.3% vs -20.8% |
PRE vs NTRA vs EXAS vs MYRG vs LH — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
PRE vs NTRA vs EXAS vs MYRG vs LH — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
MYRG leads in 2 of 6 categories
LH leads 1 • NTRA leads 1 • EXAS leads 1 • PRE leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — EXAS and LH each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
LH is the larger business by revenue, generating $14.1B annually — 204.9x PRE's $69M. LH is the more profitable business, keeping 6.7% of every revenue dollar as net income compared to PRE's -67.4%. On growth, PRE holds the edge at +2.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $69M | $2.3B | $3.2B | $3.8B | $14.1B |
| EBITDAEarnings before interest/tax | -$54M | -$310M | -$41M | $261M | $2.2B |
| Net IncomeAfter-tax profit | -$47M | -$208M | -$208M | $142M | $942M |
| Free Cash FlowCash after capex | $0 | $97M | $357M | $231M | $1.4B |
| Gross MarginGross profit ÷ Revenue | +47.2% | +64.8% | +69.7% | +11.9% | +27.8% |
| Operating MarginEBIT ÷ Revenue | -62.9% | -13.4% | -6.4% | +5.1% | +11.0% |
| Net MarginNet income ÷ Revenue | -67.4% | -9.0% | -6.4% | +3.7% | +6.7% |
| FCF MarginFCF ÷ Revenue | -23.8% | +4.2% | +11.0% | +6.0% | +9.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.0% | +39.8% | +23.1% | +20.0% | +5.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +36.9% | +185.4% | +90.4% | +106.2% | +32.9% |
Valuation Metrics
LH leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 24.7x trailing earnings, LH trades at a 57% valuation discount to MYRG's 56.8x P/E. On an enterprise value basis, LH's 12.7x EV/EBITDA is more attractive than MYRG's 28.8x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $242M | $31.2B | $20.0B | $6.7B | $21.2B |
| Enterprise ValueMkt cap + debt − cash | $212M | $30.3B | $21.6B | $6.6B | $27.9B |
| Trailing P/EPrice ÷ TTM EPS | -3.82x | -144.62x | -95.37x | 56.76x | 24.67x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 582.83x | 44.03x | 14.45x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 3.40x | — |
| EV / EBITDAEnterprise value multiple | — | — | — | 28.84x | 12.70x |
| Price / SalesMarket cap ÷ Revenue | 2.62x | 13.51x | 6.16x | 1.82x | 1.52x |
| Price / BookPrice ÷ Book value/share | 1.28x | 17.55x | 8.24x | 10.18x | 2.50x |
| Price / FCFMarket cap ÷ FCF | — | 285.53x | 56.10x | 28.66x | 17.61x |
Profitability & Efficiency
MYRG leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
MYRG delivers a 22.1% return on equity — every $100 of shareholder capital generates $22 in annual profit, vs $-29 for PRE. PRE carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to EXAS's 1.05x. On the Piotroski fundamental quality scale (0–9), MYRG scores 8/9 vs NTRA's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -28.9% | -15.3% | -8.7% | +22.1% | +10.9% |
| ROA (TTM)Return on assets | -23.7% | -10.6% | -3.5% | +8.7% | +5.1% |
| ROICReturn on invested capital | -20.8% | -36.1% | -3.6% | +18.3% | +7.8% |
| ROCEReturn on capital employed | -21.2% | -18.3% | -4.0% | +19.4% | +9.9% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 | 7 | 8 | 7 |
| Debt / EquityFinancial leverage | 0.01x | 0.13x | 1.05x | 0.16x | 0.83x |
| Net DebtTotal debt minus cash | -$30M | -$862M | $1.6B | -$47M | $6.7B |
| Cash & Equiv.Liquid assets | $32M | $1.1B | $956M | $150M | $532M |
| Total DebtShort + long-term debt | $2M | $214M | $2.5B | $104M | $7.2B |
| Interest CoverageEBIT ÷ Interest expense | -199.93x | -25.21x | -5.47x | 39.49x | 6.22x |
Total Returns (Dividends Reinvested)
NTRA leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MYRG five years ago would be worth $51,760 today (with dividends reinvested), compared to $1,393 for PRE. Over the past 12 months, PRE leads with a +205.2% total return vs LH's +6.1%. The 3-year compound annual growth rate (CAGR) favors NTRA at 60.6% vs PRE's 7.6% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +0.6% | -3.9% | +3.1% | +88.5% | +2.8% |
| 1-Year ReturnPast 12 months | +205.2% | +37.3% | +96.9% | +175.2% | +6.1% |
| 3-Year ReturnCumulative with dividends | +24.5% | +314.0% | +53.0% | +219.8% | +39.4% |
| 5-Year ReturnCumulative with dividends | -86.1% | +115.9% | +0.4% | +417.6% | +12.6% |
| 10-Year ReturnCumulative with dividends | -86.1% | +2089.4% | +1669.1% | +1680.8% | +150.7% |
| CAGR (3Y)Annualised 3-year return | +7.6% | +60.6% | +15.2% | +47.3% | +11.7% |
Risk & Volatility
EXAS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
EXAS is the less volatile stock with a 0.12 beta — it tends to amplify market swings less than MYRG's 1.70 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EXAS currently trades 99.9% from its 52-week high vs PRE's 67.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.27x | 1.26x | 0.12x | 1.70x | 0.52x |
| 52-Week HighHighest price in past year | $23.63 | $256.36 | $104.98 | $475.39 | $293.72 |
| 52-Week LowLowest price in past year | $5.07 | $131.81 | $38.81 | $152.10 | $239.67 |
| % of 52W HighCurrent price vs 52-week peak | +67.2% | +85.7% | +99.9% | +89.9% | +87.9% |
| RSI (14)Momentum oscillator 0–100 | 37.1 | 57.1 | 76.4 | 80.7 | 40.3 |
| Avg Volume (50D)Average daily shares traded | 186K | 1.3M | 4.2M | 306K | 579K |
Analyst Outlook
MYRG leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: PRE as "Buy", NTRA as "Buy", EXAS as "Buy", MYRG as "Hold", LH as "Buy". Consensus price targets imply 126.8% upside for PRE (target: $36) vs -15.3% for MYRG (target: $362). LH is the only dividend payer here at 1.11% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | $36.00 | $262.50 | $103.18 | $362.00 | $311.33 |
| # AnalystsCovering analysts | 1 | 27 | 41 | 21 | 35 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +1.1% |
| Dividend StreakConsecutive years of raises | — | — | — | 4 | 0 |
| Dividend / ShareAnnual DPS | — | — | — | — | $2.87 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.1% | +1.2% | +2.1% |
MYRG leads in 2 of 6 categories (Profitability & Efficiency, Analyst Outlook). LH leads in 1 (Valuation Metrics). 1 tied.
PRE vs NTRA vs EXAS vs MYRG vs LH: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is PRE or NTRA or EXAS or MYRG or LH a better buy right now?
For growth investors, Prenetics Global Limited (PRE) is the stronger pick with 201.
7% revenue growth year-over-year, versus 7. 2% for Labcorp Holdings Inc. (LH). Labcorp Holdings Inc. (LH) offers the better valuation at 24. 7x trailing P/E (14. 5x forward), making it the more compelling value choice. Analysts rate Prenetics Global Limited (PRE) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — PRE or NTRA or EXAS or MYRG or LH?
On trailing P/E, Labcorp Holdings Inc.
(LH) is the cheapest at 24. 7x versus MYR Group Inc. at 56. 8x. On forward P/E, Labcorp Holdings Inc. is actually cheaper at 14. 5x.
03Which is the better long-term investment — PRE or NTRA or EXAS or MYRG or LH?
Over the past 5 years, MYR Group Inc.
(MYRG) delivered a total return of +417. 6%, compared to -86. 1% for Prenetics Global Limited (PRE). Over 10 years, the gap is even starker: NTRA returned +20. 9% versus PRE's -86. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — PRE or NTRA or EXAS or MYRG or LH?
By beta (market sensitivity over 5 years), Exact Sciences Corporation (EXAS) is the lower-risk stock at 0.
12β versus MYR Group Inc. 's 1. 70β — meaning MYRG is approximately 1308% more volatile than EXAS relative to the S&P 500. On balance sheet safety, Prenetics Global Limited (PRE) carries a lower debt/equity ratio of 1% versus 105% for Exact Sciences Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — PRE or NTRA or EXAS or MYRG or LH?
By revenue growth (latest reported year), Prenetics Global Limited (PRE) is pulling ahead at 201.
7% versus 7. 2% for Labcorp Holdings Inc. (LH). On earnings-per-share growth, the picture is similar: MYR Group Inc. grew EPS 311. 5% year-over-year, compared to -14. 0% for Prenetics Global Limited. Over a 3-year CAGR, PRE leads at 91. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — PRE or NTRA or EXAS or MYRG or LH?
Labcorp Holdings Inc.
(LH) is the more profitable company, earning 6. 3% net margin versus -63. 1% for Prenetics Global Limited — meaning it keeps 6. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LH leads at 10. 9% versus -40. 5% for PRE. At the gross margin level — before operating expenses — EXAS leads at 69. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is PRE or NTRA or EXAS or MYRG or LH more undervalued right now?
On forward earnings alone, Labcorp Holdings Inc.
(LH) trades at 14. 5x forward P/E versus 582. 8x for Exact Sciences Corporation — 568. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRE: 126. 8% to $36. 00.
08Which pays a better dividend — PRE or NTRA or EXAS or MYRG or LH?
In this comparison, LH (1.
1% yield) pays a dividend. PRE, NTRA, EXAS, MYRG do not pay a meaningful dividend and should not be held primarily for income.
09Is PRE or NTRA or EXAS or MYRG or LH better for a retirement portfolio?
For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
12), +1669% 10Y return). Both have compounded well over 10 years (EXAS: +1669%, NTRA: +20. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between PRE and NTRA and EXAS and MYRG and LH?
These companies operate in different sectors (PRE (Healthcare) and NTRA (Healthcare) and EXAS (Healthcare) and MYRG (Industrials) and LH (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: PRE is a small-cap high-growth stock; NTRA is a mid-cap high-growth stock; EXAS is a mid-cap high-growth stock; MYRG is a small-cap quality compounder stock; LH is a mid-cap quality compounder stock. LH pays a dividend while PRE, NTRA, EXAS, MYRG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.